McGill Integrated Cancer Program Institute for Applied Cancer Science - PowerPoint Presentation

Slide1

McGill Integrated Cancer Program Institute for Applied Cancer Science

Achievements and Next Steps to Tackle Cancer Grand Challenges

An update for

Faculty of Medicine Retreat

December 2017

Cancer Research Continuum

Basic research is the foundation on which the cancer research continuum is built.

Cancer Research Continuum

Basic research is the foundation on which the cancer research continuum is built.WHY DO PATIENTS FAIL TO RESPOND TO THERAPIES? NEW KNOWLEDGE = NEW THERAPEUTIC STRATEGIESGenomic and other omic based technologies

Precision Oncology

97% had at least minor tumor shrinkagePercent change from baseline 40200-20-40-60-80-100

Use of molecular-based profiling of individual patient’s tumor:

Optimize patient-treatment matching

Avoid predictably ineffective, toxic and costly treatments

Improve overall clinical outcomes

Cancer diagnosis and treatment are changing

Precision Oncology

97% had at least minor tumor shrinkagePercent change from baseline 40200-20-40-60-80-100

Use of molecular-based profiling of individual patient’s tumor:

Optimize patient-treatment matching

Avoid predictably ineffective, toxic and costly treatments

Improve overall clinical outcomes

Cancer diagnosis and treatment are changing

m

olecular

pathology

Precision Oncology

97% had at least minor tumor shrinkagePercent change from baseline 40200-20-40-60-80-100

Use of molecular-based profiling of individual patient’s tumor:

Optimize patient-treatment matching

Avoid predictably ineffective, toxic and costly treatments

Improve overall clinical outcomes

Cancer diagnosis and treatment are changing

m

olecular

pathology

Precision Oncology

97% had at least minor tumor shrinkagePercent change from baseline 40200-20-40-60-80-100

Use of molecular-based profiling of individual patient’s tumor:

Optimize patient-treatment matching

Avoid predictably ineffective, toxic and costly treatments

Improve overall clinical outcomes

Cancer diagnosis and treatment are changing

Is McGill well positioned to

maximise

opportunities?

Driven by and is a driver for cancer research and innovation

The Challenge – Increased Collaboration across McGillMcGill: World-class cancer researchers; however….Relatively small teamsGeographically and administratively dispersedResources are fragmented and not centrally plannedNo McGill wide brand, identity or shared visionLack unification or integration of research efforts -clinical-basic-translationalA history of competition between units rather than collaboration

Bridging SilosInterdisciplinarityBiologistClinicianBioinformaticsEngineerStatisticianEpidemiologySystems Biology

The challenge- Funding climate is changing

Problem: Increased application pressureReduced success rates from traditional funding sources (ie. CIHR, CCS, CRS) Enhanced: Multidisciplinary large scale team grants with established track recordsRequires a fundamental shift in the way we conduct cancer research

10Models

ofCancersMolecular Profiling&PersonalizedTreatmentBiospecimen CancerBiobank&Data RepositoryClinical

Trials

• Discover New Targets

Validate Targets

• Develop Therapies

Understand Biology

Efficacy of

Precision Medicine

IMPROVE OUTCOMES

FOR HARD-TO-TREAT

CANCERS

Hard-to-Treat Cancers

Program Overview

Integrated Research Approach- Cancer Grand Challenge

unmet clinical need

11

11

Basic and Translational Research

Interdisciplinary Research

Non

FoM

Genomics/omics

Big Data Sharing

Platform Integration

Partnerships with Industry

for Target Validation and Drug Development

Knowledge Translation and Patient Impact

>8,500

Surgical Clinical and Radiological Practice

Tissue and Data Banks

Cancer

patient

population

Current Challenge –

the old model

12

Basic and Translational Research

Interdisciplinary Research

Non

FoM

Genomics/omics

Big Data Sharing

Platform Integration

Partnerships with Industry

for Target Validation and Drug Development

Knowledge Translation and Patient Impact

>8,500

Surgical Clinical and Radiological Practice

Tissue and Data Banks

Cancer

patient

population

Cancer Grand Challenge Research Approach

unmet clinical need

Goals To leverage the power of fundamental, translational and clinical research for the detection, prevention, long-term management and cure of cancers.Integrated Approach

build close integration of clinical practice with researchharmonize data warehouse-outcomes-across sitesincrease and harness clinical trials for discoverytargeted tissue and liquid biopsy repositories for discovery and validation develop multidisciplinary and interdisciplinary teams apply integrated systems approaches to understanding of disease - patient centric harness the power of multi-omic big data exploit clinical data through AI innovations-radiomics Cancer Integrated Network - Grand Challenge Research

What would a Grand Challenge Approach AccomplishImproved Non Invasive ApproachesImagingLiquid BiopsiesBiomarkersNovel Point of Care DevicesLife Style ChoicesGenetic PredispositionHost immune prevention

Point of care devicesPrecision OncologyNew therapiesSmall molecule inhibitorsAntibody-based therapiesImmune therapiesMetabolic therapiesEpigenetic therapiesImproved DetectionNovel TherapiesTumor/stroma dependenciesMetastatic nicheTumor evolution

Who would be partners at McGill?McGill Initiative in Computational MedicineBioX McGill InterdisciplinaryInitiative in Infection and Immunity (MI4) McGill Stem Cell and Regenerative Medicine NanotechnologyInnovative devicesDisruptive technologiesDisruptive biologicals

InflammationImmune modulationMicrobiomeCancer stem cellsResistanceTechnologies (IPS)

Improve Outcomes to Cancer Therapies

CANCER CHALLENGESHigh Burden CancersHigh Fatality CancersReal World EvidenceResistance to treatment and metastases PRIORITIZED THEMESNew Cancer TreatmentsNovel Cancer VulnerabilitiesMetabolic dependencies of cancersTumour

immune evasion

Synthetic lethality

New Tumor Targets

Drug repurposing

New drugs

Annotated

Tumour

Tissue Banks

Cutting Edge Technologies

-Live

Tumour

Tissue Core (PDX)

-Omics Core Facilities

-Immune Phenotyping Core

-Synthetic lethality Core

Cancer Genomics-Bioinformatics

IMPLEMENTATION STRATEGIES

Expertise-New Recruitment

Cancer Genomics-Bioinformatics

Technology Development

Forge New Partnerships

(clinicians, engineers)

Develop New Funding Opportunities

STATE OF THE ART HOSPITALS

Foster interdisciplinary multidisciplinary and interinstitutional research:

Training programs: enhance existing MICRTP partner with existing departments and programs to develop co-training models to serve as nodesSeed grants: small one-time funding opportunities to bring together new teams to tackle priority areasShared platforms and harmonization: personnel support, resource sharing and strategic planning to maximize platform usefulness and lifespanSecure large scale funding: early identification, project management and identification of co-funding for large scale initiatives (MESI, NCE, MESI, Terry Fox)What would an Integrated Cancer Network accomplish?

Training the Next Generation

Recruit the Best and Brightest in all Disciplines

Cutting-Edge

Technologies

World-Class Mentorship

Nationally and Internationally

recognized clinicians and researchers

Ground-Breaking

Interdisciplinary Research

Training

Generation

next

the

Cancer training stream

Projects at the forefront of basic

and clinically applicable cancer research

Training

through integrated core

platforms

Funding Opportunities – Ongoing Terry Fox Comprehensive Cancer Centre Network (PMH, BCCA) - Montreal Cancer Consortium (JGH, MUHC, CHUM, HMR, GCRC, IRIC) - harnessing Melanoma Network immunotherapy clinical trials - $4M/2yr Pilot ProjectTerry Fox Research Institute National Networks -

Oncopole EMC2 – Multi-institutional teams against cancer - At least 3 institutions/research centres/departments, 2 Universities - LOI: Nov. 2017 - 1.5M/3yrs – Expect to fund 4 grants-opportunities to integrate McGillMinistère de l’Economie, Science et Innovation (MESI) (LOI Dec 2017) - MCC (MUHC, CHUM, JGH, HMR, GCRC, IRIC, LDI) $20M/4 yrs high burden and high fatality increase clinical trial recruitment - Using AI to Build Radiogenomics-Based Predictors for Response to Precision Therapies in Cancer (MUHC, JGH, CHUM)

EPIC

(Pancreatic)

(PYA)

Multiple Myeloma

Fundraising – Need Partnership Approach

McGill University – Capital Campaign

funds raised can support Units at McGill

that are contributing to a

Cancer Grand

Challenge

– facilities for generation of

data from clinical material

Hospital Foundations

funds raised can support clinical

trials and tissue banking

efforts – focused on a

Cancer Grand Challenge

Motivated Donors

- want to contribute to large

research initiatives that

include partnerships

between McGill and

affiliated Hospitals

Other opportunities?

MESI, Terry Fox, NCE, SPOR

Requires a strategy to highlight that funds are being raised jointly to tackle large scale projects that span the fundamental/clinical/translational continuum of cancer research

Ongoing work and Next StepsCancer Summit

Spring 2018Strategic plan developmentEstablish working groups from all pillars Develop a governance planDefine science, priority programs and visionDetermine our needs and draft a budgetIdentify the role for donor support in a comprehensive funding planEstablish next stepsBuild our research teams and programs Generate performance metrics and comparator dataDevelop provincial, national and international partnerships

Questions